stoxline Quote Chart Rank Option Currency Glossary
  
AbCellera Biologics Inc. (ABCL)
5.05  0 (0%)    03-01 16:00
Open: 5.09
High: 5.26
Volume: 1,359,495
  
Pre. Close: 5.05
Low: 5.0016
Market Cap: 1,479(M)
Technical analysis
2024-03-01 4:50:30 PM
Short term     
Mid term     
Targets 6-month :  6.13 1-year :  6.56
Resists First :  5.24 Second :  5.61
Pivot price 5.1
Supports First :  4.65 Second :  3.86
MAs MA(5) :  5.05 MA(20) :  5.08
MA(100) :  4.91 MA(250) :  5.88
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  50.6 D(3) :  51.1
RSI RSI(14): 47.4
52-week High :  8.4 Low :  3.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABCL ] has closed above bottom band by 42.2%. Bollinger Bands are 13.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.26 - 5.29 5.29 - 5.31
Low: 4.94 - 4.97 4.97 - 4.99
Close: 5.01 - 5.05 5.05 - 5.09
Company Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Headline News

Thu, 29 Feb 2024
After losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the ... - Yahoo Finance

Thu, 29 Feb 2024
AbCellera Biologics Insiders Added US$1.61m Of Stock To Their Holdings - Simply Wall St

Wed, 28 Feb 2024
AbCellera: Victim Of Its Own Success (NASDAQ:ABCL) - Seeking Alpha

Mon, 26 Feb 2024
Federated Hermes Inc. Cuts Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat

Mon, 26 Feb 2024
AbCellera Biologics Inc. Expected to Earn FY2024 Earnings of ($0.55) Per Share (NASDAQ:ABCL) - AmericanBankingNEWS

Thu, 22 Feb 2024
AbCellera Biologics Inc (ABCL) Up 6.44% in Premarket Trading - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 293 (M)
Shares Float 188 (M)
Held by Insiders 27.9 (%)
Held by Institutions 45.7 (%)
Shares Short 24,490 (K)
Shares Short P.Month 25,580 (K)
Stock Financials
EPS -0.51
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.96
Profit Margin 0 %
Operating Margin -719.7 %
Return on Assets (ttm) -9.8 %
Return on Equity (ttm) -12.3 %
Qtrly Rev. Growth -57.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.12
EBITDA (p.s.) -0.73
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow -103 (M)
Stock Valuations
PE Ratio -9.91
PEG Ratio -0.8
Price to Book value 1.27
Price to Sales 38.88
Price to Cash Flow -33.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android